Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration

NCT: NCT05914311 · COMPLETED

NCT IDNCT05914311
StatusCOMPLETED
Start Date2023-09-08
Completion2025-02-26
SponsorWake Forest University Health Sciences (OTHER)
First posted
Last updated

Brief Summary

During the typical SCS trial the leads remain outside of the skin and can be prone to migration. The leads are typically secured in place with suture, tape, or a combination of both. This study will evaluate the amount of movement based on the method of being secured at the time of placement

Frequently Asked Questions

What is Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration?

Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration is a clinical trial registered under NCT05914311. Current status: COMPLETED.

What is the status of NCT05914311?

The current status of NCT05914311 (Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration) is: COMPLETED.

When did Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration start?

Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration started on 2023-09-08.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.